Competition Scenario in Global Immunoassays Market
The Global Immunoassays market is highly competitive with ~500 players which include globally diversified players, regional players as well as a large number of country-niche players each with their niche bioanalytical setting such as clinical diagnostics, biopharmaceutical analysis, environmental monitoring, security, and food testing, and others, for end-users. The immunoassays market’s growth is heavily reliant on detection technologies and advancements in testing equipment and instruments.
Country-Niche players constitute about ~75% of the competitors, while regional players constitute about ~20%. Some of the major players in the market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, PerkinElmer, Quidel Corporation, Ortho Clinical Diagnostics Holdings, Sysmex Corporation, DiaSorin S.p.A. and among others.
Global Immunoassays Market by geography
The Global Immunoassays market is segmented by geography into North America, Europe, Asia- pacific and LAMEA. North America accounts for the largest share among all Regions within the total Immunoassays market in 2021. Increased technological adoption in diagnostic techniques, extensive research initiatives, and increasing government funding for point-of-care testing and regulatory science activities across the healthcare industry are all contributing factors to the growth of Immunoassays in North America.
For instance, in November 2021, the U.S. Department of Health and Human Services (HHS) announced a USD 650 million investment to enhance manufacturing capacity for fast, high-quality diagnostic testing via rapid point-of-care molecular tests that help in the detection of influenza, respiratory syncytial virus (RSV), and a cluster of respiratory viruses.
What is the Expected Future Outlook for the Overall Global IMMUNOASSAYS Market Across the globe?
The Global Immunoassays market was valued at USD ~billion in 2022 and is anticipated to reach USD ~billion by the end of 2028F, witnessing a CAGR of ~% during the forecast period 2022-2028F. The realistic growth scenario represents the most likely scenario as per current market conditions. This scenario assumes that there will be no overall impact on the market due to any potential COVID-19 waves in the future.
The Global Immunoassays market is driven by rising prevalence of chronic, and infectious diseases, including COVID-19, HIV/AIDS, dengue, foodborne disease, and other diseases. However, the market is also constantly being influenced by rapid development in technology, product innovation, and diversification in some countries.
Request For Sample Report @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDkz
With the increasing innovation and emergence of new products, the Global Immunoassays market is changing rapidly. For instance, In February 2022, Siemens Healthineers, a German healthcare company, launched Enhanced Liver Fibrosis (ELF) Test in the U.S., offering broad clinical access to the nonsurgical diagnostic tool. In addition, the Food and Drug Administration (FDA) granted De Novo marketing authorization for the test.
Furthermore, In July 2021, Roche, a Swiss pharmaceutical company, announced the launch of its new Elecsys Epstein-Barr virus (EBV) immunoassay panel, which includes the Elecsys EBV IgM, EBV VCA IgG, and EBV EBNA IgG immunoassays and detects Epstein-Barr virus antibodies at various infection stages.
In April 2021, DiaSorin, an Italian Biotechnology company, launched its new immunodiagnostic Point-of-Care (POC) reader ‘LIAISON IQ’ and the ‘LIAISON Quick Detect Covid TrimericS Ab’ test. The LIAISON IQ’s test detects specific IgG antibodies against SARS-CoV-2 Spike Protein in human blood capillaries from a throat swab in 10 minutes.
The Global Immunoassays Market is forecasted to continue steady growth that is witnessed since 2017. The market is primarily driven by the rising prevalence of chronic, and infectious diseases, including COVID-19. Though the market is highly competitive with over ~500 participants, few global players control the dominant share and regional players also hold a significant share.
- Reagents & Kits
- Software & Services
- Autoimmune Diseases
- Infectious Diseases
Request For Customization @ https://www.kenresearch.com/ask-customization.php?Frmdetails=NTkyNDkz
- Radio immunoassay (RIA)
- Enzyme Immunoassays (EIA) or Enzyme-linked immunosorbent assays (ELISA)
- Fluoro Immunoassay (FIA)
- Chemiluminescence Immunoassay (CLIA)
By End User
- Hospital & Clinics
- Clinical Laboratories
- Pharmaceuticals & Biotech Companies
- Blood Banks
- Academic Research Centers
- North America (U.S., Canada, Mexico)
- Europe (Germany, UK, France, Italy, Spain, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific)
- Latin America, Middle East and Africa
For more insights on the market intelligence, refer to below link:-